CAS 1185282-03-4: N-[(1S)-2-Amino-2-oxo-1-(phenylmethyl)ethyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide

Applications APP-FUBINACA RM is an analog of AB-FUBINACA which is an indazole derivative developed as a CB1 receptor modulator used in the treatment of CB1-mediated diseases. Synthetic cannabinoids References Nahoko, U., et al.: Forensic. Toxicol., 31, 93 (2013);

APP-FUBINACA is a synthetic cannabinoid that can interact with the CB2 receptor, which belongs to the group of G protein coupled receptors. APP-FUBINACA has been shown to be potent antagonists of this receptor and is believed to be responsible for many of the adverse effects such as hallucinations, anxiety, and paranoia. APP-FUBINACA can also interact with other receptors including adrenergic receptors, serotonin receptors, dopamine receptors and opioid receptors. This drug has been shown to cause symptoms such as nausea, vomiting, agitation and insomnia. The histology of human liver cells treated with APP-FUBINACA have shown hallmarks consistent with necrosis and apoptosis. This drug is expressed in the human liver and may contribute to lesions in this area caused by chronic abuse of marijuana or other cannabinoids.

APP-FUBINACA is a cannabinoid receptor agonist, classified as a phenylalanine amide-based indazole-3-carboxamide derivative. It exhibits neurostimulatory effects.